Literature DB >> 17530366

Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate.

Takeyoshi Itsukuma1, Hideki Ishikawa, Mahito Misawa, Shunro Kai, Yoshihiro Fujimori, Kazuhiko Nakagawa, Seiichi Hirota, Ayako Sugihara, Nobuyuki Terada, Hiroshi Hara.   

Abstract

Familial adenomatous polyposis (FAP) is an autosomal dominant disorder characterized by colonic polyposis and a predisposition for developing colorectal cancer. FAP is frequently complicated by extracolonic disease, but complications of leukemia are rare. We present the first case of FAP complicated by chronic myelogenous leukemia (CML) in a 38-year-old man. The patient had numerous adenomas in the colorectum and a family history compatible with FAP. He was diagnosed as having FAP in February 2000. Two years after the diagnosis, he developed leukocytosis with the Philadelphia chromosome abnormality, indicating complication with CML. Imatinib mesylate was administered for the treatment of CML, and hematologic and cytogenetic remission of CML was achieved in 6 months. Numerous polyps, 2 to 3 mm in diameter, observed in the rectum prior to the administration of imatinib, regressed in size, but not in number, after 1 year of treatment with imatinib. Eighteen months later, however, the polyps were enlarged. In this patient, imatinib administration led to the remission of CML and might also have been responsible for the temporary regression of adenomatous polyps of FAP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17530366     DOI: 10.1007/s00535-007-2009-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  10 in total

Review 1.  Familial adenomatous polyposis (FAP) and its gene, APC.

Authors:  W Bodmer
Journal:  Cytogenet Cell Genet       Date:  1999

Review 2.  COX-2 inhibition and colorectal cancer.

Authors:  Claus-Henning Koehne; Raymond N Dubois
Journal:  Semin Oncol       Date:  2004-04       Impact factor: 4.929

3.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Authors:  E Buchdunger; C L Cioffi; N Law; D Stover; S Ohno-Jones; B J Druker; N B Lydon
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

4.  Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.

Authors:  T Nishida; S Hirota; M Taniguchi; K Hashimoto; K Isozaki; H Nakamura; Y Kanakura; T Tanaka; A Takabayashi; H Matsuda; Y Kitamura
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

Review 5.  Familial adenomatous polyposis.

Authors:  G Lal; S Gallinger
Journal:  Semin Surg Oncol       Date:  2000-06

6.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Authors:  Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

Review 7.  BCR/ABL signal transduction.

Authors:  T Tauchi; H E Broxmeyer
Journal:  Int J Hematol       Date:  1995-04       Impact factor: 2.490

8.  Acute myelocytic leukemia in two brothers with polyposis coli and carcinoma of the colon.

Authors:  M S Greenberg; K C Anderson; D J Marchetto; F P Li
Journal:  Ann Intern Med       Date:  1981-12       Impact factor: 25.391

9.  Molecular diagnosis of familial adenomatous polyposis.

Authors:  S M Powell; G M Petersen; A J Krush; S Booker; J Jen; F M Giardiello; S R Hamilton; B Vogelstein; K W Kinzler
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

10.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Authors:  B J Druker; S Tamura; E Buchdunger; S Ohno; G M Segal; S Fanning; J Zimmermann; N B Lydon
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

  10 in total
  1 in total

1.  Sporadic colonic polyposis and adenocarcinoma associated with lymphoblastic and large B-cell lymphoma in a young male patient: A case report.

Authors:  Seyed Mehdi Hashemi; Seyed Amirhossein Fazeli; Fatemeh Arabpour-Dahouei; Ali Davarian; Reza Golabchifard
Journal:  Mol Clin Oncol       Date:  2015-12-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.